Annexin A1 protects against cerebral ischemia–reperfusion injury by modulating microglia/macrophage polarization via FPR2/ALX-dependent AMPK-mTOR pathway

Abstract

Background Cerebral ischemia–reperfusion (I/R) injury is a major cause of early complications and unfavorable outcomes after endovascular thrombectomy (EVT) therapy in patients with acute ischemic stroke (AIS). Recent studies indicate that modulating microglia/macrophage polarization and subsequent inflammatory response may be a potential adjunct therapy to recanalization. Annexin A1 (ANXA1) exerts potent anti-inflammatory and pro-resolving properties in models of cerebral I/R injury. However, whether ANXA1 modulates post-I/R-induced microglia/macrophage polarization has not yet been fully elucidated. Methods We retrospectively collected blood samples from AIS patients who underwent successful recanalization by EVT and analyzed ANXA1 levels longitudinally before and after EVT and correlation between ANXA1 levels and 3-month clinical outcomes. We also established a C57BL/6J mouse model of transient middle cerebral artery occlusion/reperfusion (tMCAO/R) and an in vitro model of oxygen–glucose deprivation and reoxygenation (OGD/R) in BV2 microglia and HT22 neurons to explore the role of Ac2-26, a pharmacophore N-terminal peptide of ANXA1, in regulating the I/R-induced microglia/macrophage activation and polarization. Results The baseline levels of ANXA1 pre-EVT were significantly lower in 23 AIS patients, as compared with those of healthy controls. They were significantly increased to the levels found in controls 2–3 days post-EVT. The increased post-EVT levels of ANXA1 were positively correlated with 3-month clinical outcomes. In the mouse model, we then found that Ac2-26 administered at the start of reperfusion shifted microglia/macrophage polarization toward anti-inflammatory M2-phenotype in ischemic penumbra, thus alleviating blood–brain barrier leakage and neuronal apoptosis and improving outcomes at 3 days post-tMCAO/R. The protection was abrogated when mice received Ac2-26 together with WRW4, which is a specific antagonist of formyl peptide receptor type 2/lipoxin A4 receptor (FPR2/ALX). Furthermore, the interaction between Ac2-26 and FPR2/ALX receptor activated the 5’ adenosine monophosphate-activated protein kinase (AMPK) and inhibited the downstream mammalian target of rapamycin (mTOR). These in vivo findings were validated through in vitro experiments. Conclusions Ac2-26 modulates microglial/macrophage polarization and alleviates subsequent cerebral inflammation by regulating the FPR2/ALX-dependent AMPK-mTOR pathway. It may be investigated as an adjunct strategy for clinical prevention and treatment of cerebral I/R injury after recanalization. Plasma ANXA1 may be a potential biomarker for outcomes of AIS patients receiving EVT.

An RNA-sequencing transcriptome of the rodent Schwann cell response to peripheral nerve injury

“…Additionally, differential spatial regulation of the PI3K/Akt/mTor signaling between proximal and more distal portions of the regenerating nerve may elucidate differences between developmental and post-injury Schwann cell differentiation and myelination. In our CD45-positive myeloid cell sequencing results, we observed a significant upregulation of MAPK signaling, as reported following CNS injury [ 48 ].…”

Targeting the Annexin A1-FPR2/ALX pathway for host-directed therapy in dengue disease

“…Curiously, AnxA1 levels in human plasma were higher than in animal samples. Differences in AnxA1 plasma levels between both species have been previously noted ( Senchenkova et al, 2019 ; Xu et al, 2021 ).…”

Neuroinflammation in Cerebral Ischemia and Ischemia/Reperfusion Injuries: From Pathophysiology to Therapeutic Strategies

“…In a mouse stroke model, annexin A1 was found reduced at the onset of ischemia, followed by a return to normal levels after successful recanalization. Exogenous administration of the biologically active N-terminal peptide during reperfusion resulted in a diminished magnitude of tissue damage, likely due to a shift of microglia/macrophage cells toward M2 phenotypes via activation of the AMPK-mTOR pathway [ 251 ]. Leptin, a well-known hormone related to obesity, has also been shown to exhibit anti-inflammatory actions and to promote neuroprotection, cell differentiation, mitochondrial biogenesis, and angiogenesis [ 252 ], as well as to upregulate antioxidant defenses and anti-apoptotic proteins [ 253 ].…”